Alnylam Enjoys Autumn in Paris With hATTR Win Over Ionis
Patisiran data impresses more than inotersen but Ionis is the first to file with a European submission.
You may also be interested in...
Although Dicerna needs to make some payments to Alnylam to settle a patent infringement case, the company has avoided an expensive court trial and is free to find partners for its early-stage RNAi therapeutics programs.
The latest drug development news and highlights from our US FDA Performance Tracker.
Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.